nodes	percent_of_prediction	percent_of_DWPC	metapath
Iloperidone—CYP3A4—bone cancer	0.68	1	CbGaD
Iloperidone—HTR1D—dura mater—bone cancer	0.015	0.265	CbGeAlD
Iloperidone—HTR1D—trigeminal nerve—bone cancer	0.00645	0.114	CbGeAlD
Iloperidone—Gefitinib—CHEK2—bone cancer	0.00626	0.44	CrCbGaD
Iloperidone—HRH1—nose—bone cancer	0.00489	0.0864	CbGeAlD
Iloperidone—HTR1D—cranial nerve—bone cancer	0.0046	0.0812	CbGeAlD
Iloperidone—HTR7—cranial nerve—bone cancer	0.00366	0.0647	CbGeAlD
Iloperidone—HTR2A—trigeminal nerve—bone cancer	0.0032	0.0566	CbGeAlD
Iloperidone—Gefitinib—EGFR—bone cancer	0.0025	0.176	CrCbGaD
Iloperidone—Dyspnoea exertional—Epirubicin—bone cancer	0.00248	0.0204	CcSEcCtD
Iloperidone—Dyspnoea exertional—Doxorubicin—bone cancer	0.0023	0.0189	CcSEcCtD
Iloperidone—HTR2A—cranial nerve—bone cancer	0.00228	0.0403	CbGeAlD
Iloperidone—HTR2A—vertebral column—bone cancer	0.00224	0.0396	CbGeAlD
Iloperidone—Haematocrit decreased—Methotrexate—bone cancer	0.00215	0.0177	CcSEcCtD
Iloperidone—HTR2A—hindlimb—bone cancer	0.00192	0.034	CbGeAlD
Iloperidone—Paliperidone—CYP3A4—bone cancer	0.00181	0.128	CrCbGaD
Iloperidone—Rhinorrhoea—Cisplatin—bone cancer	0.0018	0.0148	CcSEcCtD
Iloperidone—Infection—Carboplatin—bone cancer	0.00177	0.0145	CcSEcCtD
Iloperidone—HTR2A—appendage—bone cancer	0.00165	0.0292	CbGeAlD
Iloperidone—Aphthous stomatitis—Epirubicin—bone cancer	0.0016	0.0131	CcSEcCtD
Iloperidone—Aphthous stomatitis—Doxorubicin—bone cancer	0.00148	0.0121	CcSEcCtD
Iloperidone—Body temperature increased—Carboplatin—bone cancer	0.0014	0.0115	CcSEcCtD
Iloperidone—Fluid retention—Cisplatin—bone cancer	0.00139	0.0114	CcSEcCtD
Iloperidone—Cisapride—CYP3A4—bone cancer	0.00137	0.0967	CrCbGaD
Iloperidone—Risperidone—CYP3A4—bone cancer	0.00135	0.0951	CrCbGaD
Iloperidone—Nasal congestion—Cisplatin—bone cancer	0.00116	0.00955	CcSEcCtD
Iloperidone—Renal failure acute—Cisplatin—bone cancer	0.00115	0.00943	CcSEcCtD
Iloperidone—Amnesia—Cisplatin—bone cancer	0.00113	0.00926	CcSEcCtD
Iloperidone—Nystagmus—Epirubicin—bone cancer	0.00105	0.00862	CcSEcCtD
Iloperidone—Dehydration—Cisplatin—bone cancer	0.000986	0.00809	CcSEcCtD
Iloperidone—Nystagmus—Doxorubicin—bone cancer	0.000972	0.00798	CcSEcCtD
Iloperidone—Orthostatic hypotension—Cisplatin—bone cancer	0.000968	0.00795	CcSEcCtD
Iloperidone—Hypokalaemia—Cisplatin—bone cancer	0.000965	0.00792	CcSEcCtD
Iloperidone—Breast disorder—Cisplatin—bone cancer	0.000958	0.00786	CcSEcCtD
Iloperidone—HTR1D—connective tissue—bone cancer	0.000948	0.0168	CbGeAlD
Iloperidone—Nasopharyngitis—Cisplatin—bone cancer	0.000948	0.00778	CcSEcCtD
Iloperidone—Gefitinib—CYP3A4—bone cancer	0.000914	0.0643	CrCbGaD
Iloperidone—Blood disorder—Epirubicin—bone cancer	0.000898	0.00737	CcSEcCtD
Iloperidone—Musculoskeletal stiffness—Methotrexate—bone cancer	0.000894	0.00733	CcSEcCtD
Iloperidone—Abdominal discomfort—Cisplatin—bone cancer	0.000879	0.00721	CcSEcCtD
Iloperidone—Delirium—Epirubicin—bone cancer	0.000872	0.00716	CcSEcCtD
Iloperidone—Breast pain—Epirubicin—bone cancer	0.00086	0.00706	CcSEcCtD
Iloperidone—Amenorrhoea—Epirubicin—bone cancer	0.000854	0.00701	CcSEcCtD
Iloperidone—Blood disorder—Doxorubicin—bone cancer	0.000831	0.00682	CcSEcCtD
Iloperidone—Delirium—Doxorubicin—bone cancer	0.000807	0.00662	CcSEcCtD
Iloperidone—Dyskinesia—Epirubicin—bone cancer	0.000798	0.00655	CcSEcCtD
Iloperidone—Stomatitis—Cisplatin—bone cancer	0.000797	0.00654	CcSEcCtD
Iloperidone—Breast pain—Doxorubicin—bone cancer	0.000796	0.00653	CcSEcCtD
Iloperidone—Conjunctivitis—Cisplatin—bone cancer	0.000794	0.00652	CcSEcCtD
Iloperidone—Amenorrhoea—Doxorubicin—bone cancer	0.00079	0.00648	CcSEcCtD
Iloperidone—Hepatobiliary disease—Cisplatin—bone cancer	0.000773	0.00634	CcSEcCtD
Iloperidone—Gait disturbance—Epirubicin—bone cancer	0.000769	0.00631	CcSEcCtD
Iloperidone—HTR7—connective tissue—bone cancer	0.000755	0.0134	CbGeAlD
Iloperidone—Dyskinesia—Doxorubicin—bone cancer	0.000739	0.00606	CcSEcCtD
Iloperidone—Salivary hypersecretion—Epirubicin—bone cancer	0.000729	0.00598	CcSEcCtD
Iloperidone—Mouth ulceration—Methotrexate—bone cancer	0.000725	0.00595	CcSEcCtD
Iloperidone—Urinary tract disorder—Cisplatin—bone cancer	0.000724	0.00595	CcSEcCtD
Iloperidone—Connective tissue disorder—Cisplatin—bone cancer	0.000721	0.00592	CcSEcCtD
Iloperidone—Urethral disorder—Cisplatin—bone cancer	0.000719	0.0059	CcSEcCtD
Iloperidone—Gynaecomastia—Methotrexate—bone cancer	0.000717	0.00589	CcSEcCtD
Iloperidone—Fluid retention—Epirubicin—bone cancer	0.000712	0.00585	CcSEcCtD
Iloperidone—Gait disturbance—Doxorubicin—bone cancer	0.000711	0.00584	CcSEcCtD
Iloperidone—Dry eye—Epirubicin—bone cancer	0.000693	0.00569	CcSEcCtD
Iloperidone—Eye disorder—Cisplatin—bone cancer	0.000686	0.00563	CcSEcCtD
Iloperidone—Tinnitus—Cisplatin—bone cancer	0.000684	0.00561	CcSEcCtD
Iloperidone—Cardiac disorder—Cisplatin—bone cancer	0.000681	0.00559	CcSEcCtD
Iloperidone—Mouth ulceration—Epirubicin—bone cancer	0.000678	0.00557	CcSEcCtD
Iloperidone—Salivary hypersecretion—Doxorubicin—bone cancer	0.000674	0.00553	CcSEcCtD
Iloperidone—Mediastinal disorder—Cisplatin—bone cancer	0.000661	0.00543	CcSEcCtD
Iloperidone—Fluid retention—Doxorubicin—bone cancer	0.000659	0.00541	CcSEcCtD
Iloperidone—Arrhythmia—Cisplatin—bone cancer	0.000655	0.00538	CcSEcCtD
Iloperidone—Dry eye—Doxorubicin—bone cancer	0.000641	0.00526	CcSEcCtD
Iloperidone—Malnutrition—Cisplatin—bone cancer	0.000639	0.00524	CcSEcCtD
Iloperidone—Renal failure acute—Methotrexate—bone cancer	0.00063	0.00517	CcSEcCtD
Iloperidone—Mouth ulceration—Doxorubicin—bone cancer	0.000628	0.00515	CcSEcCtD
Iloperidone—HTR2C—spinal cord—bone cancer	0.000623	0.011	CbGeAlD
Iloperidone—Muscle spasms—Cisplatin—bone cancer	0.000614	0.00504	CcSEcCtD
Iloperidone—SIGMAR1—tendon—bone cancer	0.000608	0.0107	CbGeAlD
Iloperidone—Vision blurred—Cisplatin—bone cancer	0.000602	0.00494	CcSEcCtD
Iloperidone—Tremor—Cisplatin—bone cancer	0.000598	0.00491	CcSEcCtD
Iloperidone—Lethargy—Methotrexate—bone cancer	0.000594	0.00487	CcSEcCtD
Iloperidone—Anaemia—Cisplatin—bone cancer	0.00059	0.00484	CcSEcCtD
Iloperidone—Renal failure acute—Epirubicin—bone cancer	0.00059	0.00484	CcSEcCtD
Iloperidone—SIGMAR1—bone marrow—bone cancer	0.000589	0.0104	CbGeAlD
Iloperidone—SIGMAR1—spinal cord—bone cancer	0.000586	0.0104	CbGeAlD
Iloperidone—Increased appetite—Epirubicin—bone cancer	0.00058	0.00476	CcSEcCtD
Iloperidone—Leukopenia—Cisplatin—bone cancer	0.000572	0.00469	CcSEcCtD
Iloperidone—HRH1—connective tissue—bone cancer	0.000564	0.00997	CbGeAlD
Iloperidone—Cardiac failure—Epirubicin—bone cancer	0.000558	0.00458	CcSEcCtD
Iloperidone—Lethargy—Epirubicin—bone cancer	0.000556	0.00456	CcSEcCtD
Iloperidone—ADRA2A—connective tissue—bone cancer	0.000554	0.00979	CbGeAlD
Iloperidone—Mood swings—Methotrexate—bone cancer	0.000551	0.00452	CcSEcCtD
Iloperidone—Renal failure acute—Doxorubicin—bone cancer	0.000546	0.00448	CcSEcCtD
Iloperidone—Myalgia—Cisplatin—bone cancer	0.000544	0.00446	CcSEcCtD
Iloperidone—Increased appetite—Doxorubicin—bone cancer	0.000536	0.0044	CcSEcCtD
Iloperidone—Affect lability—Epirubicin—bone cancer	0.000536	0.0044	CcSEcCtD
Iloperidone—Breast disorder—Methotrexate—bone cancer	0.000526	0.00432	CcSEcCtD
Iloperidone—HTR1A—spinal cord—bone cancer	0.000524	0.00926	CbGeAlD
Iloperidone—Oedema—Cisplatin—bone cancer	0.000521	0.00428	CcSEcCtD
Iloperidone—HTR7—tendon—bone cancer	0.000519	0.00918	CbGeAlD
Iloperidone—Infection—Cisplatin—bone cancer	0.000518	0.00425	CcSEcCtD
Iloperidone—Cardiac failure—Doxorubicin—bone cancer	0.000516	0.00424	CcSEcCtD
Iloperidone—Mood swings—Epirubicin—bone cancer	0.000516	0.00423	CcSEcCtD
Iloperidone—Lethargy—Doxorubicin—bone cancer	0.000514	0.00422	CcSEcCtD
Iloperidone—Nervous system disorder—Cisplatin—bone cancer	0.000511	0.00419	CcSEcCtD
Iloperidone—Tachycardia—Cisplatin—bone cancer	0.000509	0.00417	CcSEcCtD
Iloperidone—Dehydration—Epirubicin—bone cancer	0.000506	0.00416	CcSEcCtD
Iloperidone—Asthma—Methotrexate—bone cancer	0.000503	0.00413	CcSEcCtD
Iloperidone—HTR7—spinal cord—bone cancer	0.000501	0.00885	CbGeAlD
Iloperidone—Orthostatic hypotension—Epirubicin—bone cancer	0.000497	0.00408	CcSEcCtD
Iloperidone—Affect lability—Doxorubicin—bone cancer	0.000496	0.00407	CcSEcCtD
Iloperidone—Hypokalaemia—Epirubicin—bone cancer	0.000496	0.00407	CcSEcCtD
Iloperidone—Breast disorder—Epirubicin—bone cancer	0.000492	0.00404	CcSEcCtD
Iloperidone—Hypotension—Cisplatin—bone cancer	0.000487	0.004	CcSEcCtD
Iloperidone—Nasopharyngitis—Epirubicin—bone cancer	0.000487	0.004	CcSEcCtD
Iloperidone—Abdominal discomfort—Methotrexate—bone cancer	0.000482	0.00396	CcSEcCtD
Iloperidone—Gastritis—Epirubicin—bone cancer	0.000482	0.00396	CcSEcCtD
Iloperidone—Mood swings—Doxorubicin—bone cancer	0.000477	0.00392	CcSEcCtD
Iloperidone—ADRA2C—tendon—bone cancer	0.000477	0.00844	CbGeAlD
Iloperidone—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000475	0.0039	CcSEcCtD
Iloperidone—HTR2A—connective tissue—bone cancer	0.000471	0.00833	CbGeAlD
Iloperidone—Asthma—Epirubicin—bone cancer	0.000471	0.00386	CcSEcCtD
Iloperidone—Dysuria—Methotrexate—bone cancer	0.00047	0.00386	CcSEcCtD
Iloperidone—Dehydration—Doxorubicin—bone cancer	0.000469	0.00385	CcSEcCtD
Iloperidone—Paraesthesia—Cisplatin—bone cancer	0.000468	0.00384	CcSEcCtD
Iloperidone—Upper respiratory tract infection—Methotrexate—bone cancer	0.000467	0.00384	CcSEcCtD
Iloperidone—Dyspnoea—Cisplatin—bone cancer	0.000465	0.00381	CcSEcCtD
Iloperidone—Erectile dysfunction—Methotrexate—bone cancer	0.000463	0.0038	CcSEcCtD
Iloperidone—ADRA2C—spinal cord—bone cancer	0.00046	0.00814	CbGeAlD
Iloperidone—Orthostatic hypotension—Doxorubicin—bone cancer	0.00046	0.00378	CcSEcCtD
Iloperidone—Hypokalaemia—Doxorubicin—bone cancer	0.000459	0.00376	CcSEcCtD
Iloperidone—Breast disorder—Doxorubicin—bone cancer	0.000455	0.00374	CcSEcCtD
Iloperidone—Nasopharyngitis—Doxorubicin—bone cancer	0.000451	0.0037	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Cisplatin—bone cancer	0.00045	0.00369	CcSEcCtD
Iloperidone—Gastritis—Doxorubicin—bone cancer	0.000446	0.00366	CcSEcCtD
Iloperidone—Dysuria—Epirubicin—bone cancer	0.00044	0.00361	CcSEcCtD
Iloperidone—Upper respiratory tract infection—Epirubicin—bone cancer	0.000437	0.00359	CcSEcCtD
Iloperidone—Stomatitis—Methotrexate—bone cancer	0.000437	0.00359	CcSEcCtD
Iloperidone—Conjunctivitis—Methotrexate—bone cancer	0.000436	0.00358	CcSEcCtD
Iloperidone—Asthma—Doxorubicin—bone cancer	0.000435	0.00357	CcSEcCtD
Iloperidone—Pollakiuria—Epirubicin—bone cancer	0.000435	0.00357	CcSEcCtD
Iloperidone—Feeling abnormal—Cisplatin—bone cancer	0.000429	0.00352	CcSEcCtD
Iloperidone—Weight increased—Epirubicin—bone cancer	0.000428	0.00352	CcSEcCtD
Iloperidone—Weight decreased—Epirubicin—bone cancer	0.000426	0.00349	CcSEcCtD
Iloperidone—Hepatobiliary disease—Methotrexate—bone cancer	0.000424	0.00348	CcSEcCtD
Iloperidone—Epistaxis—Methotrexate—bone cancer	0.000423	0.00347	CcSEcCtD
Iloperidone—Body temperature increased—Cisplatin—bone cancer	0.000412	0.00338	CcSEcCtD
Iloperidone—Stomatitis—Epirubicin—bone cancer	0.000409	0.00336	CcSEcCtD
Iloperidone—Conjunctivitis—Epirubicin—bone cancer	0.000408	0.00335	CcSEcCtD
Iloperidone—Dysuria—Doxorubicin—bone cancer	0.000407	0.00334	CcSEcCtD
Iloperidone—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000405	0.00332	CcSEcCtD
Iloperidone—Pollakiuria—Doxorubicin—bone cancer	0.000402	0.0033	CcSEcCtD
Iloperidone—Urinary tract disorder—Methotrexate—bone cancer	0.000398	0.00326	CcSEcCtD
Iloperidone—Hepatobiliary disease—Epirubicin—bone cancer	0.000397	0.00326	CcSEcCtD
Iloperidone—Weight increased—Doxorubicin—bone cancer	0.000396	0.00325	CcSEcCtD
Iloperidone—Epistaxis—Epirubicin—bone cancer	0.000396	0.00325	CcSEcCtD
Iloperidone—Urethral disorder—Methotrexate—bone cancer	0.000395	0.00324	CcSEcCtD
Iloperidone—Weight decreased—Doxorubicin—bone cancer	0.000394	0.00323	CcSEcCtD
Iloperidone—HRH1—tendon—bone cancer	0.000388	0.00685	CbGeAlD
Iloperidone—ADRA2A—tendon—bone cancer	0.000381	0.00673	CbGeAlD
Iloperidone—Stomatitis—Doxorubicin—bone cancer	0.000378	0.00311	CcSEcCtD
Iloperidone—Conjunctivitis—Doxorubicin—bone cancer	0.000377	0.0031	CcSEcCtD
Iloperidone—Eye disorder—Methotrexate—bone cancer	0.000376	0.00309	CcSEcCtD
Iloperidone—Tinnitus—Methotrexate—bone cancer	0.000375	0.00308	CcSEcCtD
Iloperidone—Asthenia—Cisplatin—bone cancer	0.000374	0.00307	CcSEcCtD
Iloperidone—Cardiac disorder—Methotrexate—bone cancer	0.000374	0.00307	CcSEcCtD
Iloperidone—CYP2E1—tendon—bone cancer	0.000373	0.00658	CbGeAlD
Iloperidone—Urinary tract disorder—Epirubicin—bone cancer	0.000372	0.00305	CcSEcCtD
Iloperidone—Connective tissue disorder—Epirubicin—bone cancer	0.00037	0.00304	CcSEcCtD
Iloperidone—Urethral disorder—Epirubicin—bone cancer	0.000369	0.00303	CcSEcCtD
Iloperidone—ADRA2A—spinal cord—bone cancer	0.000367	0.00649	CbGeAlD
Iloperidone—Hepatobiliary disease—Doxorubicin—bone cancer	0.000367	0.00301	CcSEcCtD
Iloperidone—Epistaxis—Doxorubicin—bone cancer	0.000366	0.00301	CcSEcCtD
Iloperidone—Angiopathy—Methotrexate—bone cancer	0.000365	0.003	CcSEcCtD
Iloperidone—Mediastinal disorder—Methotrexate—bone cancer	0.000363	0.00298	CcSEcCtD
Iloperidone—CYP2E1—spinal cord—bone cancer	0.000359	0.00635	CbGeAlD
Iloperidone—Diarrhoea—Cisplatin—bone cancer	0.000357	0.00293	CcSEcCtD
Iloperidone—Mental disorder—Methotrexate—bone cancer	0.000353	0.00289	CcSEcCtD
Iloperidone—Eye disorder—Epirubicin—bone cancer	0.000352	0.00289	CcSEcCtD
Iloperidone—Tinnitus—Epirubicin—bone cancer	0.000351	0.00288	CcSEcCtD
Iloperidone—Malnutrition—Methotrexate—bone cancer	0.00035	0.00288	CcSEcCtD
Iloperidone—Cardiac disorder—Epirubicin—bone cancer	0.00035	0.00287	CcSEcCtD
Iloperidone—Urinary tract disorder—Doxorubicin—bone cancer	0.000344	0.00283	CcSEcCtD
Iloperidone—Connective tissue disorder—Doxorubicin—bone cancer	0.000343	0.00281	CcSEcCtD
Iloperidone—Angiopathy—Epirubicin—bone cancer	0.000342	0.00281	CcSEcCtD
Iloperidone—Urethral disorder—Doxorubicin—bone cancer	0.000342	0.0028	CcSEcCtD
Iloperidone—Mediastinal disorder—Epirubicin—bone cancer	0.00034	0.00279	CcSEcCtD
Iloperidone—Arrhythmia—Epirubicin—bone cancer	0.000337	0.00276	CcSEcCtD
Iloperidone—Vision blurred—Methotrexate—bone cancer	0.00033	0.00271	CcSEcCtD
Iloperidone—Mental disorder—Epirubicin—bone cancer	0.00033	0.00271	CcSEcCtD
Iloperidone—Rash—Cisplatin—bone cancer	0.000329	0.0027	CcSEcCtD
Iloperidone—Dermatitis—Cisplatin—bone cancer	0.000328	0.00269	CcSEcCtD
Iloperidone—Malnutrition—Epirubicin—bone cancer	0.000328	0.00269	CcSEcCtD
Iloperidone—Eye disorder—Doxorubicin—bone cancer	0.000326	0.00267	CcSEcCtD
Iloperidone—Tinnitus—Doxorubicin—bone cancer	0.000325	0.00267	CcSEcCtD
Iloperidone—Anaemia—Methotrexate—bone cancer	0.000324	0.00266	CcSEcCtD
Iloperidone—HTR2A—tendon—bone cancer	0.000324	0.00572	CbGeAlD
Iloperidone—Cardiac disorder—Doxorubicin—bone cancer	0.000324	0.00266	CcSEcCtD
Iloperidone—Angiopathy—Doxorubicin—bone cancer	0.000316	0.0026	CcSEcCtD
Iloperidone—Muscle spasms—Epirubicin—bone cancer	0.000315	0.00259	CcSEcCtD
Iloperidone—Vertigo—Methotrexate—bone cancer	0.000315	0.00258	CcSEcCtD
Iloperidone—Mediastinal disorder—Doxorubicin—bone cancer	0.000314	0.00258	CcSEcCtD
Iloperidone—Leukopenia—Methotrexate—bone cancer	0.000314	0.00257	CcSEcCtD
Iloperidone—HTR2A—spinal cord—bone cancer	0.000312	0.00552	CbGeAlD
Iloperidone—Arrhythmia—Doxorubicin—bone cancer	0.000311	0.00256	CcSEcCtD
Iloperidone—Nausea—Cisplatin—bone cancer	0.00031	0.00254	CcSEcCtD
Iloperidone—Vision blurred—Epirubicin—bone cancer	0.000309	0.00254	CcSEcCtD
Iloperidone—Mental disorder—Doxorubicin—bone cancer	0.000305	0.00251	CcSEcCtD
Iloperidone—Malnutrition—Doxorubicin—bone cancer	0.000303	0.00249	CcSEcCtD
Iloperidone—Anaemia—Epirubicin—bone cancer	0.000303	0.00249	CcSEcCtD
Iloperidone—Agitation—Epirubicin—bone cancer	0.000301	0.00247	CcSEcCtD
Iloperidone—Arthralgia—Methotrexate—bone cancer	0.000298	0.00245	CcSEcCtD
Iloperidone—Myalgia—Methotrexate—bone cancer	0.000298	0.00245	CcSEcCtD
Iloperidone—Vertigo—Epirubicin—bone cancer	0.000295	0.00242	CcSEcCtD
Iloperidone—Leukopenia—Epirubicin—bone cancer	0.000294	0.00241	CcSEcCtD
Iloperidone—Muscle spasms—Doxorubicin—bone cancer	0.000292	0.00239	CcSEcCtD
Iloperidone—Palpitations—Epirubicin—bone cancer	0.00029	0.00238	CcSEcCtD
Iloperidone—Confusional state—Methotrexate—bone cancer	0.000288	0.00237	CcSEcCtD
Iloperidone—Vision blurred—Doxorubicin—bone cancer	0.000286	0.00235	CcSEcCtD
Iloperidone—Infection—Methotrexate—bone cancer	0.000284	0.00233	CcSEcCtD
Iloperidone—Nervous system disorder—Methotrexate—bone cancer	0.00028	0.0023	CcSEcCtD
Iloperidone—Anaemia—Doxorubicin—bone cancer	0.00028	0.0023	CcSEcCtD
Iloperidone—Arthralgia—Epirubicin—bone cancer	0.000279	0.00229	CcSEcCtD
Iloperidone—Myalgia—Epirubicin—bone cancer	0.000279	0.00229	CcSEcCtD
Iloperidone—Agitation—Doxorubicin—bone cancer	0.000279	0.00229	CcSEcCtD
Iloperidone—Dry mouth—Epirubicin—bone cancer	0.000273	0.00224	CcSEcCtD
Iloperidone—Vertigo—Doxorubicin—bone cancer	0.000273	0.00224	CcSEcCtD
Iloperidone—Leukopenia—Doxorubicin—bone cancer	0.000272	0.00223	CcSEcCtD
Iloperidone—Confusional state—Epirubicin—bone cancer	0.00027	0.00221	CcSEcCtD
Iloperidone—Palpitations—Doxorubicin—bone cancer	0.000268	0.0022	CcSEcCtD
Iloperidone—Oedema—Epirubicin—bone cancer	0.000268	0.0022	CcSEcCtD
Iloperidone—Hypotension—Methotrexate—bone cancer	0.000267	0.00219	CcSEcCtD
Iloperidone—Infection—Epirubicin—bone cancer	0.000266	0.00218	CcSEcCtD
Iloperidone—Nervous system disorder—Epirubicin—bone cancer	0.000262	0.00215	CcSEcCtD
Iloperidone—Tachycardia—Epirubicin—bone cancer	0.000261	0.00214	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000261	0.00214	CcSEcCtD
Iloperidone—Arthralgia—Doxorubicin—bone cancer	0.000258	0.00212	CcSEcCtD
Iloperidone—Myalgia—Doxorubicin—bone cancer	0.000258	0.00212	CcSEcCtD
Iloperidone—Paraesthesia—Methotrexate—bone cancer	0.000257	0.00211	CcSEcCtD
Iloperidone—Dyspnoea—Methotrexate—bone cancer	0.000255	0.00209	CcSEcCtD
Iloperidone—Somnolence—Methotrexate—bone cancer	0.000254	0.00209	CcSEcCtD
Iloperidone—Dry mouth—Doxorubicin—bone cancer	0.000253	0.00207	CcSEcCtD
Iloperidone—Hypotension—Epirubicin—bone cancer	0.00025	0.00205	CcSEcCtD
Iloperidone—Confusional state—Doxorubicin—bone cancer	0.00025	0.00205	CcSEcCtD
Iloperidone—Oedema—Doxorubicin—bone cancer	0.000248	0.00203	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Methotrexate—bone cancer	0.000247	0.00203	CcSEcCtD
Iloperidone—Fatigue—Methotrexate—bone cancer	0.000247	0.00202	CcSEcCtD
Iloperidone—Infection—Doxorubicin—bone cancer	0.000246	0.00202	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000244	0.002	CcSEcCtD
Iloperidone—Nervous system disorder—Doxorubicin—bone cancer	0.000243	0.00199	CcSEcCtD
Iloperidone—Tachycardia—Doxorubicin—bone cancer	0.000242	0.00198	CcSEcCtD
Iloperidone—Paraesthesia—Epirubicin—bone cancer	0.00024	0.00197	CcSEcCtD
Iloperidone—Dyspnoea—Epirubicin—bone cancer	0.000239	0.00196	CcSEcCtD
Iloperidone—Somnolence—Epirubicin—bone cancer	0.000238	0.00195	CcSEcCtD
Iloperidone—Feeling abnormal—Methotrexate—bone cancer	0.000236	0.00193	CcSEcCtD
Iloperidone—Hypotension—Doxorubicin—bone cancer	0.000231	0.0019	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Epirubicin—bone cancer	0.000231	0.0019	CcSEcCtD
Iloperidone—Fatigue—Epirubicin—bone cancer	0.000231	0.00189	CcSEcCtD
Iloperidone—Body temperature increased—Methotrexate—bone cancer	0.000226	0.00186	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000226	0.00185	CcSEcCtD
Iloperidone—Paraesthesia—Doxorubicin—bone cancer	0.000222	0.00183	CcSEcCtD
Iloperidone—Dyspnoea—Doxorubicin—bone cancer	0.000221	0.00181	CcSEcCtD
Iloperidone—Feeling abnormal—Epirubicin—bone cancer	0.000221	0.00181	CcSEcCtD
Iloperidone—Somnolence—Doxorubicin—bone cancer	0.00022	0.00181	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000214	0.00175	CcSEcCtD
Iloperidone—Fatigue—Doxorubicin—bone cancer	0.000214	0.00175	CcSEcCtD
Iloperidone—Body temperature increased—Epirubicin—bone cancer	0.000212	0.00174	CcSEcCtD
Iloperidone—Asthenia—Methotrexate—bone cancer	0.000205	0.00168	CcSEcCtD
Iloperidone—Feeling abnormal—Doxorubicin—bone cancer	0.000204	0.00167	CcSEcCtD
Iloperidone—Body temperature increased—Doxorubicin—bone cancer	0.000196	0.00161	CcSEcCtD
Iloperidone—Diarrhoea—Methotrexate—bone cancer	0.000196	0.00161	CcSEcCtD
Iloperidone—Asthenia—Epirubicin—bone cancer	0.000192	0.00158	CcSEcCtD
Iloperidone—Dizziness—Methotrexate—bone cancer	0.000189	0.00155	CcSEcCtD
Iloperidone—Diarrhoea—Epirubicin—bone cancer	0.000183	0.0015	CcSEcCtD
Iloperidone—Rash—Methotrexate—bone cancer	0.00018	0.00148	CcSEcCtD
Iloperidone—Dermatitis—Methotrexate—bone cancer	0.00018	0.00148	CcSEcCtD
Iloperidone—Asthenia—Doxorubicin—bone cancer	0.000178	0.00146	CcSEcCtD
Iloperidone—Dizziness—Epirubicin—bone cancer	0.000177	0.00145	CcSEcCtD
Iloperidone—Nausea—Methotrexate—bone cancer	0.00017	0.00139	CcSEcCtD
Iloperidone—Diarrhoea—Doxorubicin—bone cancer	0.000169	0.00139	CcSEcCtD
Iloperidone—Rash—Epirubicin—bone cancer	0.000169	0.00139	CcSEcCtD
Iloperidone—Dermatitis—Epirubicin—bone cancer	0.000169	0.00138	CcSEcCtD
Iloperidone—Dizziness—Doxorubicin—bone cancer	0.000164	0.00134	CcSEcCtD
Iloperidone—Nausea—Epirubicin—bone cancer	0.000159	0.0013	CcSEcCtD
Iloperidone—Rash—Doxorubicin—bone cancer	0.000156	0.00128	CcSEcCtD
Iloperidone—Dermatitis—Doxorubicin—bone cancer	0.000156	0.00128	CcSEcCtD
Iloperidone—Nausea—Doxorubicin—bone cancer	0.000147	0.00121	CcSEcCtD
Iloperidone—HRH1—Signaling Pathways—GRM1—bone cancer	4.88e-05	0.000382	CbGpPWpGaD
Iloperidone—ADRA2C—Metabolism—ENO2—bone cancer	4.87e-05	0.000381	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling by GPCR—GNA11—bone cancer	4.85e-05	0.00038	CbGpPWpGaD
Iloperidone—ADRA2A—GPCR downstream signaling—IL3—bone cancer	4.84e-05	0.00038	CbGpPWpGaD
Iloperidone—HTR2A—Signaling by GPCR—IL3—bone cancer	4.83e-05	0.000379	CbGpPWpGaD
Iloperidone—HRH1—Signaling by GPCR—IL3—bone cancer	4.82e-05	0.000378	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—GRM1—bone cancer	4.79e-05	0.000375	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling by GPCR—IL3—bone cancer	4.73e-05	0.000371	CbGpPWpGaD
Iloperidone—DRD2—Circadian rythm related genes—TP53—bone cancer	4.72e-05	0.00037	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—GNA11—bone cancer	4.71e-05	0.000369	CbGpPWpGaD
Iloperidone—CYP3A7—Metabolism—DHFR—bone cancer	4.65e-05	0.000364	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—NDUFA12—bone cancer	4.64e-05	0.000364	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—SMO—bone cancer	4.63e-05	0.000363	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—ATF1—bone cancer	4.58e-05	0.000359	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—SMO—bone cancer	4.57e-05	0.000358	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—ATF1—bone cancer	4.57e-05	0.000358	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—ATF1—bone cancer	4.54e-05	0.000356	CbGpPWpGaD
Iloperidone—ADRA2C—Metabolism—DHFR—bone cancer	4.51e-05	0.000354	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—IL3—bone cancer	4.46e-05	0.00035	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—IL3—bone cancer	4.46e-05	0.00035	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—GRM1—bone cancer	4.45e-05	0.000348	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—IL3—bone cancer	4.43e-05	0.000347	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling by GPCR—IL3—bone cancer	4.4e-05	0.000345	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—ATF1—bone cancer	4.38e-05	0.000343	CbGpPWpGaD
Iloperidone—CYP3A7—Metabolism—GNA11—bone cancer	4.34e-05	0.00034	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—IL3—bone cancer	4.27e-05	0.000335	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—GNA11—bone cancer	4.24e-05	0.000332	CbGpPWpGaD
Iloperidone—ADRA2C—Metabolism—GNA11—bone cancer	4.22e-05	0.000331	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—GNA11—bone cancer	4.18e-05	0.000328	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—SMO—bone cancer	3.99e-05	0.000312	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—SMO—bone cancer	3.96e-05	0.000311	CbGpPWpGaD
Iloperidone—ADRA2A—Metabolism—ENO2—bone cancer	3.95e-05	0.00031	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—ATF1—bone cancer	3.94e-05	0.000309	CbGpPWpGaD
Iloperidone—CYP3A7—Metabolism—CYP3A4—bone cancer	3.94e-05	0.000309	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—ATF1—bone cancer	3.89e-05	0.000305	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—SMO—bone cancer	3.86e-05	0.000302	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—NT5C3A—bone cancer	3.84e-05	0.000301	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—IL3—bone cancer	3.84e-05	0.000301	CbGpPWpGaD
Iloperidone—ADRA2C—Metabolism—CYP3A4—bone cancer	3.82e-05	0.0003	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—TGFBR2—bone cancer	3.82e-05	0.000299	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—TGFBR2—bone cancer	3.81e-05	0.000299	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—IL3—bone cancer	3.79e-05	0.000297	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—TGFBR2—bone cancer	3.79e-05	0.000297	CbGpPWpGaD
Iloperidone—ADRA2A—Metabolism—DHFR—bone cancer	3.67e-05	0.000287	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—TGFBR2—bone cancer	3.65e-05	0.000286	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—GNA11—bone cancer	3.65e-05	0.000286	CbGpPWpGaD
Iloperidone—CYP2E1—Metabolism—ENO2—bone cancer	3.63e-05	0.000284	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—GNA11—bone cancer	3.63e-05	0.000284	CbGpPWpGaD
Iloperidone—CYP3A5—Metabolism—ENO2—bone cancer	3.62e-05	0.000284	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—IGF1R—bone cancer	3.59e-05	0.000282	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—IGF1R—bone cancer	3.59e-05	0.000281	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—IGF1R—bone cancer	3.57e-05	0.000279	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—GNA11—bone cancer	3.53e-05	0.000276	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—SMO—bone cancer	3.5e-05	0.000274	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—SMO—bone cancer	3.44e-05	0.00027	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—SMO—bone cancer	3.44e-05	0.000269	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—IGF1R—bone cancer	3.44e-05	0.000269	CbGpPWpGaD
Iloperidone—ADRA2A—Metabolism—GNA11—bone cancer	3.43e-05	0.000269	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—ATF1—bone cancer	3.39e-05	0.000266	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—ATF1—bone cancer	3.37e-05	0.000264	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—SMO—bone cancer	3.37e-05	0.000264	CbGpPWpGaD
Iloperidone—CYP3A7—Metabolism—GSTP1—bone cancer	3.37e-05	0.000264	CbGpPWpGaD
Iloperidone—CYP2E1—Metabolism—DHFR—bone cancer	3.37e-05	0.000264	CbGpPWpGaD
Iloperidone—CYP3A5—Metabolism—DHFR—bone cancer	3.36e-05	0.000263	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—IL3—bone cancer	3.3e-05	0.000259	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—IL3—bone cancer	3.29e-05	0.000258	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—TGFBR2—bone cancer	3.29e-05	0.000258	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—ATF1—bone cancer	3.28e-05	0.000257	CbGpPWpGaD
Iloperidone—ADRA2C—Metabolism—GSTP1—bone cancer	3.27e-05	0.000256	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—TGFBR2—bone cancer	3.24e-05	0.000254	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—GNA11—bone cancer	3.2e-05	0.000251	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—IL3—bone cancer	3.2e-05	0.000251	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—GNA11—bone cancer	3.15e-05	0.000247	CbGpPWpGaD
Iloperidone—CYP2E1—Metabolism—GNA11—bone cancer	3.15e-05	0.000247	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—GNA11—bone cancer	3.14e-05	0.000246	CbGpPWpGaD
Iloperidone—CYP3A5—Metabolism—GNA11—bone cancer	3.14e-05	0.000246	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—SMO—bone cancer	3.13e-05	0.000246	CbGpPWpGaD
Iloperidone—ADRA2A—Metabolism—CYP3A4—bone cancer	3.11e-05	0.000243	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—IGF1R—bone cancer	3.09e-05	0.000242	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—GNA11—bone cancer	3.08e-05	0.000242	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—IGF1R—bone cancer	3.05e-05	0.000239	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—ATF1—bone cancer	2.98e-05	0.000233	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—ATF1—bone cancer	2.93e-05	0.000229	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—ATF1—bone cancer	2.92e-05	0.000229	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—IL3—bone cancer	2.9e-05	0.000227	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—ATF1—bone cancer	2.87e-05	0.000225	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—GNA11—bone cancer	2.86e-05	0.000225	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—IL3—bone cancer	2.85e-05	0.000224	CbGpPWpGaD
Iloperidone—CYP2E1—Metabolism—CYP3A4—bone cancer	2.85e-05	0.000224	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—IL3—bone cancer	2.85e-05	0.000223	CbGpPWpGaD
Iloperidone—CYP3A5—Metabolism—CYP3A4—bone cancer	2.85e-05	0.000223	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—TGFBR2—bone cancer	2.83e-05	0.000222	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—TGFBR2—bone cancer	2.81e-05	0.00022	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—IL3—bone cancer	2.8e-05	0.000219	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—TGFBR2—bone cancer	2.73e-05	0.000214	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—ATF1—bone cancer	2.66e-05	0.000209	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—IGF1R—bone cancer	2.66e-05	0.000208	CbGpPWpGaD
Iloperidone—ADRA2A—Metabolism—GSTP1—bone cancer	2.66e-05	0.000208	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—IGF1R—bone cancer	2.65e-05	0.000207	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—KIT—bone cancer	2.61e-05	0.000204	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—KIT—bone cancer	2.6e-05	0.000204	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—IL3—bone cancer	2.6e-05	0.000204	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—KIT—bone cancer	2.59e-05	0.000203	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—ENO2—bone cancer	2.58e-05	0.000202	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—IGF1R—bone cancer	2.57e-05	0.000202	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—KIT—bone cancer	2.49e-05	0.000195	CbGpPWpGaD
Iloperidone—ADRA2C—Hemostasis—TP53—bone cancer	2.49e-05	0.000195	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—TGFBR2—bone cancer	2.48e-05	0.000195	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—BRAF—bone cancer	2.45e-05	0.000192	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—BRAF—bone cancer	2.45e-05	0.000192	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—TGFBR2—bone cancer	2.44e-05	0.000191	CbGpPWpGaD
Iloperidone—CYP2E1—Metabolism—GSTP1—bone cancer	2.44e-05	0.000191	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—TGFBR2—bone cancer	2.44e-05	0.000191	CbGpPWpGaD
Iloperidone—CYP3A5—Metabolism—GSTP1—bone cancer	2.43e-05	0.000191	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—BRAF—bone cancer	2.43e-05	0.00019	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—TGFBR2—bone cancer	2.39e-05	0.000187	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—DHFR—bone cancer	2.39e-05	0.000187	CbGpPWpGaD
Iloperidone—HTR6—Signaling by GPCR—EGFR—bone cancer	2.37e-05	0.000186	CbGpPWpGaD
Iloperidone—HTR7—Signaling by GPCR—EGFR—bone cancer	2.37e-05	0.000186	CbGpPWpGaD
Iloperidone—HTR1D—Signaling by GPCR—EGFR—bone cancer	2.36e-05	0.000185	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—BRAF—bone cancer	2.34e-05	0.000184	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—IGF1R—bone cancer	2.33e-05	0.000183	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—IGF1R—bone cancer	2.3e-05	0.00018	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—IGF1R—bone cancer	2.29e-05	0.00018	CbGpPWpGaD
Iloperidone—DRD4—Signaling by GPCR—EGFR—bone cancer	2.27e-05	0.000178	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—IGF1R—bone cancer	2.25e-05	0.000176	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—KIT—bone cancer	2.24e-05	0.000176	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—GNA11—bone cancer	2.23e-05	0.000175	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—TGFBR2—bone cancer	2.22e-05	0.000174	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—KIT—bone cancer	2.21e-05	0.000173	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—ENO2—bone cancer	2.18e-05	0.000171	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—BRAF—bone cancer	2.11e-05	0.000165	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—IGF1R—bone cancer	2.09e-05	0.000164	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—BRAF—bone cancer	2.08e-05	0.000163	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—MDM2—bone cancer	2.05e-05	0.000161	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—MDM2—bone cancer	2.05e-05	0.000161	CbGpPWpGaD
Iloperidone—DRD1—Signaling by GPCR—EGFR—bone cancer	2.04e-05	0.00016	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—MDM2—bone cancer	2.04e-05	0.00016	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—CYP3A4—bone cancer	2.02e-05	0.000159	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—DHFR—bone cancer	2.02e-05	0.000159	CbGpPWpGaD
Iloperidone—ADRA2A—Hemostasis—TP53—bone cancer	2.02e-05	0.000158	CbGpPWpGaD
Iloperidone—DRD3—Signaling by GPCR—EGFR—bone cancer	2.02e-05	0.000158	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—MDM2—bone cancer	1.96e-05	0.000154	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—KIT—bone cancer	1.93e-05	0.000151	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—KIT—bone cancer	1.92e-05	0.00015	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—GNA11—bone cancer	1.89e-05	0.000148	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—KIT—bone cancer	1.87e-05	0.000146	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—BRAF—bone cancer	1.81e-05	0.000142	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—BRAF—bone cancer	1.8e-05	0.000141	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—JUN—bone cancer	1.78e-05	0.00014	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—JUN—bone cancer	1.78e-05	0.00014	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—JUN—bone cancer	1.77e-05	0.000139	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—MDM2—bone cancer	1.77e-05	0.000138	CbGpPWpGaD
Iloperidone—HTR1A—Signaling by GPCR—EGFR—bone cancer	1.76e-05	0.000138	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—BRAF—bone cancer	1.75e-05	0.000137	CbGpPWpGaD
Iloperidone—HTR2C—Signaling by GPCR—EGFR—bone cancer	1.75e-05	0.000137	CbGpPWpGaD
Iloperidone—CYP3A7—Metabolism—PTGS2—bone cancer	1.74e-05	0.000137	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—MDM2—bone cancer	1.74e-05	0.000137	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—MMP9—bone cancer	1.74e-05	0.000136	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—MMP9—bone cancer	1.73e-05	0.000136	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—GSTP1—bone cancer	1.73e-05	0.000136	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—MMP9—bone cancer	1.72e-05	0.000135	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—CYP3A4—bone cancer	1.71e-05	0.000134	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.71e-05	0.000134	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—JUN—bone cancer	1.71e-05	0.000134	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling by GPCR—EGFR—bone cancer	1.7e-05	0.000133	CbGpPWpGaD
Iloperidone—ADRA2C—Metabolism—PTGS2—bone cancer	1.69e-05	0.000133	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—KIT—bone cancer	1.69e-05	0.000133	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—ENO2—bone cancer	1.68e-05	0.000132	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—KIT—bone cancer	1.67e-05	0.000131	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—KIT—bone cancer	1.66e-05	0.00013	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—MMP9—bone cancer	1.66e-05	0.00013	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—KIT—bone cancer	1.63e-05	0.000128	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—BRAF—bone cancer	1.59e-05	0.000125	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—BRAF—bone cancer	1.57e-05	0.000123	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—BRAF—bone cancer	1.56e-05	0.000122	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—DHFR—bone cancer	1.56e-05	0.000122	CbGpPWpGaD
Iloperidone—DRD2—Signaling by GPCR—EGFR—bone cancer	1.54e-05	0.000121	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—JUN—bone cancer	1.54e-05	0.00012	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—BRAF—bone cancer	1.53e-05	0.00012	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—MDM2—bone cancer	1.52e-05	0.000119	CbGpPWpGaD
Iloperidone—HTR2A—Signaling by GPCR—EGFR—bone cancer	1.52e-05	0.000119	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—KIT—bone cancer	1.52e-05	0.000119	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—JUN—bone cancer	1.51e-05	0.000119	CbGpPWpGaD
Iloperidone—HRH1—Signaling by GPCR—EGFR—bone cancer	1.51e-05	0.000119	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—MDM2—bone cancer	1.51e-05	0.000118	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—MMP9—bone cancer	1.49e-05	0.000117	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling by GPCR—EGFR—bone cancer	1.49e-05	0.000117	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—MMP9—bone cancer	1.47e-05	0.000116	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—MDM2—bone cancer	1.47e-05	0.000115	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—GSTP1—bone cancer	1.47e-05	0.000115	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—GNA11—bone cancer	1.46e-05	0.000114	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—BRAF—bone cancer	1.42e-05	0.000112	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—EGFR—bone cancer	1.4e-05	0.00011	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—EGFR—bone cancer	1.4e-05	0.00011	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—EGFR—bone cancer	1.39e-05	0.000109	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling by GPCR—EGFR—bone cancer	1.38e-05	0.000108	CbGpPWpGaD
Iloperidone—ADRA2A—Metabolism—PTGS2—bone cancer	1.38e-05	0.000108	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—EGFR—bone cancer	1.34e-05	0.000105	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—MDM2—bone cancer	1.33e-05	0.000105	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—JUN—bone cancer	1.32e-05	0.000103	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—JUN—bone cancer	1.31e-05	0.000103	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—MDM2—bone cancer	1.31e-05	0.000103	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—MDM2—bone cancer	1.31e-05	0.000103	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—MDM2—bone cancer	1.28e-05	0.000101	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—MMP9—bone cancer	1.28e-05	0.000101	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—MMP9—bone cancer	1.28e-05	0.0001	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—JUN—bone cancer	1.28e-05	0.0001	CbGpPWpGaD
Iloperidone—CYP2E1—Metabolism—PTGS2—bone cancer	1.26e-05	9.91e-05	CbGpPWpGaD
Iloperidone—CYP3A5—Metabolism—PTGS2—bone cancer	1.26e-05	9.89e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—MMP9—bone cancer	1.24e-05	9.74e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—EGFR—bone cancer	1.21e-05	9.46e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—MDM2—bone cancer	1.19e-05	9.36e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—EGFR—bone cancer	1.19e-05	9.34e-05	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—TP53—bone cancer	1.18e-05	9.23e-05	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—TP53—bone cancer	1.18e-05	9.22e-05	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—TP53—bone cancer	1.17e-05	9.16e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—JUN—bone cancer	1.16e-05	9.09e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—JUN—bone cancer	1.14e-05	8.94e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—JUN—bone cancer	1.14e-05	8.92e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—GSTP1—bone cancer	1.13e-05	8.87e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—MMP9—bone cancer	1.13e-05	8.84e-05	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—TP53—bone cancer	1.13e-05	8.82e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—JUN—bone cancer	1.12e-05	8.75e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—MMP9—bone cancer	1.11e-05	8.7e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—MMP9—bone cancer	1.11e-05	8.68e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—MMP9—bone cancer	1.09e-05	8.52e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—EGFR—bone cancer	1.04e-05	8.14e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—JUN—bone cancer	1.04e-05	8.13e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—EGFR—bone cancer	1.03e-05	8.09e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—TP53—bone cancer	1.01e-05	7.94e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—MMP9—bone cancer	1.01e-05	7.91e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—EGFR—bone cancer	1e-05	7.87e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—TP53—bone cancer	1e-05	7.84e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—EGFR—bone cancer	9.11e-06	7.14e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—PTGS2—bone cancer	8.97e-06	7.03e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—EGFR—bone cancer	8.97e-06	7.03e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—EGFR—bone cancer	8.95e-06	7.01e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—EGFR—bone cancer	8.78e-06	6.88e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—TP53—bone cancer	8.72e-06	6.83e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—TP53—bone cancer	8.67e-06	6.8e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—TP53—bone cancer	8.43e-06	6.61e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—EGFR—bone cancer	8.16e-06	6.39e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—TP53—bone cancer	7.65e-06	6e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—PTGS2—bone cancer	7.6e-06	5.96e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—TP53—bone cancer	7.53e-06	5.9e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—TP53—bone cancer	7.51e-06	5.89e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—TP53—bone cancer	7.37e-06	5.78e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—TP53—bone cancer	6.85e-06	5.37e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—PTGS2—bone cancer	5.86e-06	4.6e-05	CbGpPWpGaD
